ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Information Officer Plays Key Role In Cancer Program

February 8, 1980

Senate Calls Cancer Research a Priority, Cites Research Task Force Funding Goal

October 8, 1999

Garb Points Out Cancer Program Is Saving ore Lives a Year Than Polio Vaccine

April 6, 1979

New Policy on Minor Changes in Trials Requires Halt in Patient Enrollment.

April 25, 2008

Fox Chase Joins Plan For Free Cancer Screening

May 9, 1986

Drug Development Gets Extra $500,000

November 18, 1977